Ref: M H L/Sec&Legal/2020/72

To,

HeadJ Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

Scrip Code:542650

Dear Sir/Madam,

Date: February 06, 2020

Head, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1 . G Block, Sandra -Kurla Complex, Sandra (East), Mumbai- 400051

Scrip Symbol: METROPOLIS

Sub: Outcome of the Board Meeting pursuant to Regulation 30 and33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements} Regulations 2016 ('SEBI Listing Regulations').

We wish to inform you that pursuant to the applicable provisions of SEBI Listing Regulations, the Board of Directors (the ''Board'') at its meeting held today i.e. February 06, 2020, inter­alia considered and approved the following:

a) The Unaudited (Standalone & Consolidated) Financ;:ial Results of the Company for the quarter and nine months ended December 31 , 2019 and Limited Review Report issued by BSR & Co. LLP.

b) The- payment of Interim Dividend of Rs.8/- (Rupees Eight Only) per equity share of the face value of Rs. 2/~ (Rupee Two Only) each for the financial year 2019-20. The interim dividend will be paid to the members whose names appears in the Register of Members I Register of beneficiaries as on the 'Record Date' i.e. Saturday·, February 15, 2020. The Interim Dividend will be paid to the entitled shareholders within 30 days of declaration.

Accordingly, we enclose herewith the following:

1. Unaudited Standalone financial results along with the Limited Review Report. 2. Unaudited Consolidated financial results along with the Limited Review report.

The above information Is also being made available on the website of the Company.

The aforesaid Board Meeting commenced at 2.00 pm and concluded at&..3Ppm.

We request you to kindly take the same on record and acknowledge the receipt of the same.

Thanking you.

Yours Faithfully,

For Metr~althcare Limited

A~ushil Shah Managing Director (DIN: 00208095)

METROPI}LIS The Pathology Specialist

INNER HEALTH REVEALED Metropolis Healthcare Limited 1\cgl~tcred Office: 250 D. Udyog Bhavan, Hfnd Cycle Mirg, Worli, Mumbai • 400 o; CIN; U73 I OOMHlOOOPLC 192798. Tel: +91-22-3399 3939 I 6650 SSSS. Email: support®mavopo1i•indl"-com I Website. www metropoll<lndl~.com Central L.abor.~tory: ~th Floor, Colllmercl31 Building- lA. Kohlnoor Mall,

Vidy~vih•r \'N), Mumbal - 100 070.

B S R & Co. LLP Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India

Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Limited review report on Unaudited Qu arterly Standalone Financial Results and Standalone Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Metropolis I-Iealthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis 1-lcaJthcare Limited ('the Company') for the quarter ended 31 December2019 and year to date results for the period from 1 Apri l 2019 to 31 December 2019 (''the Statement''). Attention is drawn to the fact that the standalone figures for lhe corresponding quarter ended 31 December 20 18 and corresponding period from 1 April 20 I & to 31 December 2018, as reported in these financial results have been approved by the Board ofDirectors, but have not been subjected to review, since the equity shares of the Company were listed on the stock exchanges during the quarter ended 30 June 2019.

2. This Statement, which is the responsibility of the Company's management and approved by Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in lndiru1 Accounting Standard 34 "Interim Financial Reporting" ( .. lnd AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in cornpliruJce with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 241 0 ''Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This stru1dard requires that we plan and perfonn the review to obtain moderate assurance as to whether the Statement is free of materia l misstatement. 1\ review is limited primru·ily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not perfonned an audit and accordingly, we do not express an audit opinion.

6 S R 8t Co t• f"'r1n~r•h ip lirm Wolh Re\jlstratlnn No. BA61223) converted Into B S R & Co ~~P to Limitod U~~llitY, Partnership with LLP Fl•gls~r~tirm No. MB·8181I with oflect ft om Octoh<lr 14, 2013

Reo,~••md Oflic.,_ 6111 Aoor, Lodh., Excelus Apollo Mills Compound N. M . Joshi Marg, M~hol&xn11 Mumb8i - 400 011. Indio

B S R & Co. LLP

Limited review report on Unaudited Quarterly Standalone Financial Results and Standalone Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards an.d other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Mumbai 06 February 2020

For B S R & Co. LLP Chartered Accountants

Finn Registration No: 101 248W/W. J00022

Metropolis Oealtbcarc Limited

Unaudited Standalone Financial Results for the quarter find nine months ended 31 December 2019

JJ December Sr.

rullcula~ 2019 o. {l)oaudited)

I Income

s )Rcwcnuc: (rum operanoru 17,290 97

b) Other mcomc 178 49

'!olllllocomc 17.~69.46

2 'E:xpensCJ~

n) C:ost of mnterl;tl cor\iumcd <1 ,264 67

b) Laboratory tesnng charges 128.89

c) Employc:c bcnefib Cllpcnsc 3,806.30

d) l'm1111ce costs 183 04

e) Deprecia!ton and amottisatinn expcn~ 815.21

t) Other ~ICfll'n~c$ 4,27L75

Tot1il E:xp~oJ~.!I 13,470.!16

3 Profit beforfl e:rcrpticmal itcur ~nd tax (J)- (2) 3,999 00

" Exc;;ciJtluualltc.nu (rdcr note 4 ) . s l'rOiil hefMe. tax (3). (4) 3,999.00

6 T11x exfl6Me.

C\lTTcnt u.x 1146 I 0

DcJCm:d tAX (income ) I expc:nse (76.94)

T ut.al tax exprn~n 76SU6

7 Pruflt for the p~riod I yeir (5) --(6) 3.2~9.84

8 Olher compnbrn5ivc Income

hems that will not be r~ltN•Iied subKquc:nUy to p•uflt and (5.44)

lo>'!l (net of1a.x)

H~ms that will be subsequenlly rcclassilied lo profit AIId loss (net of lAX) Qtber comprebcn~lve Income /(lon) Cot Che 11erlod I yC!Br

(5.44) (net of ta:x)

9 Total comprehensive intome (7) + (8) 3,'Z24.40

10 P;nd-up elJut t:y shllle capt tal (flu:~ ltUiue • Rs. 2 per share) 1,003.57

II Other ~qu1ty

12 Eammgs per sbti"' (ofRs.2 eacb) basrc; • (k t) • 1!.44

Eaminss per shnre (ofRs.l C!11ch) drlutcd- (Rs.) • 6 4l

("nOt ll.nnU4hscd)

See ncc<lnlpanying notes to Lhe unnudited standalone LinanciaLrcsults

METROPI'LIS The Pathology Specialist

(Rs io Lakhs) OuRrl~r ended Nine 1\fuoths endrd Year ended

30 September 31 Drccmber 3'1 D~crmber 31 December 31 )\{'arch 2019 2019 20 111 lOJ9 20 L8 (Audited)

(l}uauditcd) (Unaudited) (Unaudited) (Unaudited) (refer note 7) (rcfrr ROle 7)

17.228.28 14,579 07 50,215. 19 4;!.,673 05 $8,12081

98..17 - )$9 67 626.72 2,052.32

17.326.75 14.5?9.01 ~0.~74.86 43,.304,77 (10,173.13

4,266 08 3,342.31 12,478.97 10,427 03 13,907 64

173 18 177.17 437 QS J07 84 469 16

3,816.36 3.422,53 11,272.7] 10,397 74 t3,694.67

166 83 1,96 496.20 33.37 51 83

149 88 409 95 J,236 77 1.115 55 l.S43 S7

~,344,98 3,nl9s 12,460.41 11.348.22 15,587.33

13,Sl7.3J 11,281.87 39,383.05 33,629.7~ 45,254.20

3,80944 3,19720 11 ,191 81 9.675 02 14.918 93

. - b86.48

3,809.44 3,197:20 10r~OS.J3 9,675.02. 14,918.93

611 55 1, 14138 2,283.30 3.420 00 4,717 00

30.17 (124 41) (7 SO) 58.97 56.23

641.72 1,016.97 ;!.,275.80 3,478.!17 4.773.23

J,L67.72 2,280.23 8,229.53 6.196.05 IO,J4S.70

(1 16.06) 34.S1 ( 114 04) 34.31 '343

8140 . . (116.06) I 15.91 (114.04) 34.31 33.43

3,0!!1.66 2,396.14 8,115.49 6,230.36 10.179.13

1,003 57 1.003 S1 1.003.57 1,00_3.57 1,003,57

40,536 83

631 4 S1 16.40 12.43 2032

6)0 4.51 16.37 12 40 20.28

INNER HEALTH REVEALED Metropolis Healthcare Limited Reaistered Office: 250 0 , Udyog Blu van, Hind Cycle Marg. Wo1li, Mumbal - 400 0 CIN: U731 00MHlOOOPLC I92796. Tel: +91-21.-3399 3939/6650 SSSS. Em•il: support@mcrropolislndla.,orn I Websl1e; www ~ •etropoli•indll.com

Contr:>l l abor.ltory: 4th Floor, Cornn•erclaJ Buildhlg· l A, Kohinoor M~ll.

Vldyavih~r CW), Mumb•i • 400 070.

Metmpolislfcalthcare Limited

OTES:

These financial results have been prepar.ed in accordance with U1e re~:og:n!~ion and measurement prl.nciples of lnlllatt A,ecmmltng StiUldil!!)S ('' fud AS") prescn11ed under Sec;uon 133 of the Companies Act, 20 13 read with the relevant r.uJes issued lll.:reundt:t and U1e other qCcounting principles generally aecepted in India

2 The nbovc unaudited res~tlts were reviewed by theAuclit Committee at U1eir aneeling held on 06 Febroary 2020 11Dd th~:;reafter approved by the Board ofDirectors at th~ir meeting h!"ld on 06 February 2020. llle staturory auditors hnve exprcs~cd an tllllllodified revieW opinion.

3 The Compuny h!IS adopted llld AS 11 6, effective annual reporting period beginning April l, 20J 9 and appl]ed the standard to its leases, retro ·pccl.iveJy, witb the curnulutive effect Of initially applying the ~tandard, recogpised ori the date of iuithll applicatiou (Aprill, 201 9) Accordingly, the Company 1111.~ Ml Jt!;h-lh:d compnrntive lnfmm:atjon, instead, the cwnulative effect of inililllly applying U1is Sl.ill!dard hilS been recognjsed as an adjustment to the openln_g baiMce of ret!tined earnings as on April 1. 2019. "Ibe Company has ndopted Ind AS 116 using the cumulative effect method for transition mg.

4 Exceptional items in lhe financial results for the nine month ended 31 Deeember 2019 includes: • a) provi.~1on for impnlnne!II-Of !nvelitmenl in sec;unnes of lnfrastrocturG Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 L.akhs and; b) provisioo for Rs.350.QO lakhs on ulicOunt of eortaln ol~ unrcconcilcd balances.

5 Disc1osure of segment • wise Information is nol applicable, as pathology servic~ is U1e Company only busiu~~s segmenL

6 1lle Company completed an lllilial Public Offer U1rough an offer for sule by the selllng ~hl!feholders of I ,36,85,095 equity shares ofRs.2 each at price of Rs. 880. ·o1e equity shares of the Company got lisLed on the 13SE Limited o.nd NaLionnl Stnek Exchange of India Limited on 15 April 20 19 .B~tpcm;es reluted tQ the offer nrc bomg nrc bcmg borne by selling shareholders.

7 The stsnd!\lone lio.ancial resuh-s for lbe quarter ended 31 December 2018 and nine months ended 31 December 2018 were not subjected to limited review by Lbe Statutory Ullditors Md nrc: as prcpurc:d by the Company's management.

8 Tho Company have: elected to exc:rotse Lbc option pc:rmrttcd Ltnder section I 15-BAA of the lncorne-ta.x Act, J 961 as iutroduccd by the Ttl.>i~Lion ~ws (Amendment) Ordlnllllce, 2019 Acc,;orillngly, the Company have re~;ognlsed ProvtsiOn of Income Tax for the nine months ended JJ Dect:tnber 2019 and rc-mt:I!Sured its Deferr~d Tax As~ets bMis the rate: prescribed in the said section. The full impact of this change bas be~n reCQgn.Q;ed in Ute SWtement of Profit & LO$S for the gunrter ende.d 30 September 10 19 and nine months period ended 31 December 20 19.

9 The- Company is in process of acquiring 51% shareholdlnf: of Shraddha Diagnostic Centre (I) Private Llmit.ed for-providing diagnostic and pathologtgnJ testing services in AhmedabadT Gujarat as approved in Board Meeting held qn 15 January 2020 ro wenglhen the presence of Lhe CornpUrty in the Slate of G!ljurai for purchase: C~Jnsidcrati!JD of Rs. 936.30 lakhs. The same is expected to be closed w!U1in 3 rnomhs from the date of approvul of U1c Bo.u-d. .

10 The Board of Directors of the Company have approved the !litc:rim dividend orRs. 8 per equity share (Face value oi its. 2 each:) at the meeting held on 06 February 2020.

11 Th.c r~ults of the Company are avrulable for mvestors- at www.metropolisialclia.com, WI\ \\' n:o>e 111dJU. co 1m and \ HYw bst·m,hn ~.:om.

Ameera Shah

Managing Dlrelltor DlN : 00208095

Place: Mumbai

METROP- LIS The Pathology Specialist

INNER HEALTH REVEALED Metropolis Healthcare Limited Registered Orll~e: 250 D. Udyog Bh>v!i!l, Hind Cycle M;trz, W o rli, Murnb~i • '100 030. CIN: U731 OOMH2000PLC 192798. Tel: +91 .22.3399 3939 /6650 5555,

Emall: support@ metr opolislndl:t.tom I W~b•ite: www.nletropoli•ind i:~.com

Central Labm·atory: ~th Floor, Cort1n1ertl~l Building. lA, Kot11noor Mall, Vidyavlhar C'N), Mumbai - 400 070.

B S R & Co. LLP Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai • 400 011 India

Telephone +91 (22) 4345 6300 Fax +91 (22) 4345 5399

Limited review report on Unaudited Quarterly Consolidated Financial Results and Consolidated Year-to-Date Results of Metropolis Health care Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Metropolis Healthcare Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of

Metropolis Healthcare Limited ("the Parent'') and its subsidiaries (the Parent and its subsidiaries together refe1Ted to as "the Group"), and its share of the net (loss) after tax and total comprehensive loss of its joint venture for the quarter ended 31 December 2019 and year to date results for tbe period from 1 Apri I 2019 to 3 J December 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regt1lations, 2015, as amended ('Listing Regulations;). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31 December 2018 and corresponding period from 1 April2018 to 31 December 2018, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the equity shares of the Parent were listed on the stock exchanges during the quarter ended 30 June 2019.

2. This Statement, which is the responsibility ofthe Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measmement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting"' ("lnd AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 ofthe Listing Regulations. Our responsibi lity is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SR.E) 2410 "Review of Interim Financial Information Perfonned by the Independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. A review of interim financial infom1ation consists of making inquiries, primari ly of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by lhc SEBI under Regulation 33(8) oftbe Listing Regulations, to the extent applicable.

4. The Statement includes result of the entities as stated in Annexure l

B S A & Co fa patV>e• ship firm with Rogislralion No. BA81223) converted into B S R & Co. lLP fa Umiled Uabiliry, P~ttfl!lrsllil' wilh LlP Rogistratinn No. AAB·8181) with effect from Octobor 14. 2013

Rogistorod Off.,.,: Sth Floor, lodh~ E""lus Apollo Mills Compound N. M. Joshi Ma1g, Mahala•ml Mumbai • 400 011. India

B S R & Co. LLP

Limited review report on Unaudited Quartcdy Consolidated Financial Results and Consolidated Year-to-Date Results of Metropolis Health care Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid lndian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the infom1ation required to be disclosed in tenns of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the interim financial results of6 (six) subsidiaries which have not been reviewed, whose interim financial results reflect total revenue of Rs.l ,031.33 Lakhs and Rs. 3,187.52 Lakhs, total net (loss) after tax of Rs. 7.37 Lakhs and profit after tax of Rs. 74.82 Lakhs and total comprehensive income ofRs. 12.15 Lakhs and Rs. 79.11 Lakhs for the quarter ended 31 December 20 19 and for the period from I April 2019 to 31 December 20 t 9, respectively, as considered in the Statement. According to the infonnation and explanations given to us by the management, these interim financia l results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Mumbai 06 February 2020

For B S R & Co. LLP Chartered Accountants

Fim1 Registration No: 101248W/ W·I00022

*~·,n l.nger arlnl!r

L \ Membersh~ No: l 05003

JCAl lJDIN: 20105003AMAAD7254

8 S R & Co. LLP

Annexure I

List of entities included in the consolidated financial results:

Sr No

2

3

4

5

6

7

8

9

10

ll

12

13

14

15 16

17

Name of E ntity

Sudharma Metropolis Health Services Private Limited

Bokil Golwilkar Mel!opolis Hllalthcare Private Limited

Raj Metropolis Hcahhc11re Privnte Limit~d

Desai Metropolis Health Services Private Limited

R.V. Metropolis Diagnostics & Health Care Centre Private Limited

Micron Mlltropolis Healtbcare Private Limited

Dr. Patel Metropolis Healthcare Private Limited

L11b One Metropolis H.:ulthc;ll'e Services Private Limited

Amin's Pathology Laboratory Private Limited

Ekopath Metropolis Lab Servi~es Private Limited

Metropolis Healthcare Lanka (Pvt) Limited

Metropolis Healthcare (Mauritius) Limited

Metropolis Star Lab Kenya Limited

Metropolis HeaJthcarc Ghana Limited

Metropolis Brams.:r Lab Services (Mtius) Limited

Metropolis Healthcarc (Tanzania) Limited

Metropolis Histoxpert Digital Services Private Limited

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

SubsidiilJ'Y

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Subsidiary

Joint Venture

lor. ,\o,

l

J

~

9

10

11

12

13

14

IS

10

17

\ '\ctrOpQii\ ll c.a llh~"" Llm ltl!d

• hne mtn l of Con~tJiillnled Fin a n cilll Rt·~ull> for the quarter nnt.l nim· rnonlh~ enrlcd 3 I December 2019

Particulmn Jl Decem~r 10 19

(Un.uJilud)

lncom~

al Rev~nue from NlcratiOOt 1U8~ 18

b) Othu mcame 118<l5

Totallncomr ll.50~.J3

ExpeDUS

• I Cost ofm.olmnl consumed 'i2J:!.JO

b 1 L.abora:o!'! tcsuna chaf¥eos l :!J 0

c) l:.mpluxcc ~=fal> t~ptnSI: 4,84 JJ

d) fumnce cwts !:19 58

e) Dcprccaa!Jon or.d amor.tJallon •l<Jim!• I,C!SS 'll t I O!hl!f t\JM'J!M's S.1E07

T otal E:.penou 17,!2U.l

Profit before es:cept.ionallltm:J. share of profit ror fQUi&"' J,17'111?

accountrd inVotrr> ond IMOttltiU. (I)- (;l)

f.xcepliooal llen11 (R•f• r nut< 5)

Pro lit bcfnr• share of profit fur « 1uiQ' accuunttd lnvtstns ~.210 AO

and tar tJI· r~1

Share orto« rnr ~quit" atcountr d invext•• • (nr t oft~<)

Profit before rat (5) - (6) 5,179.88

I A~0W~~

t utftF.l ...... • .113~2

::kferred mx (ll'.:<r.r) nperu<! (05011

Tot~ la.x apUIJ.H 1,078.50

Profit for l.ho prriodly .. r (7) -{8) 4~0].39

Q1heo;r r.nmf'reh en.dYe Income

ltccu that -.all nl)l ~ rcc:n6stlttd !ubsQqumclv :o P!Ofn and !CISI tS.Jol

l~tl oftA•) llcrr .. Uw wrll b< lui>>equcrnlv rcc:atJ1ftcd !O- ptolit l!ld lDis (n~t

tlt of :a.,) UtbRf c.ompt i!.ln•nsh f (lou) llnromt for I he 11erfod~cor (not o

(0.15) tul

Tot•l comprrbensh•r income (91.,. (10) ~.%01 .24

Profi!/ (lou) attributa~lr to:

0\\Te<S .. r 11c Co:npanv 4 ""'07 , ...

~'"'" .;on•ronma mierc$~ I~ SJl

Ot~tir t oanproh•nsive (lou) / lnoome.11ttribur•blo to:

U"r<N of tht C'cl'!.)ld~V (0 l,

NUT! controllm)ol. mtttci\ IOU I I

Tolal comprehenJive lnl"ome I (I on) auribullble co: 0..11ea oflht Con:pill!\ .l:Z,CSIUt\

r\O:J"'CDal!oUrntt :n•(tc.s: p !hi

Pii.J-.p C<JUI1\ ·rn..· .:.>pt•ol ( t~<e '~ !l$ ~ Ollr sho..-e) I,DQ.1S7

O~or <quat) (utd~Jt~~ \~n-wr.•to'h~~ tntrr~)

Cal1tl 'II> l)Cl ~ t (Face v.;"• of R$ 'C4<h) b;t$1c fR•) • fi JS

f.Jirnti.~'Ji iJe! r!-.J.rt (F'~t:r \'.&.UC' u!"Rs ~ C'old'l) c!:. ... ~rd tR>) . S37

('co·:rr~c)

'\ • ..: •ccnmpiln~ mg not.: tu th.: wtlluli~d cansu!:d.at.:d futMCIW roults

( R~. in Lakbs) (.lu at~,.tnd~u 'Iii nee ~looU.. Endod \ u' rndl'll

JO S•ptrmbrr JJ IJec;,mhtr

.llDetvmbtr JJ D..:ember

l018 2018 31 ,\lar(b lOJQ l 019 2019

(Unaudited) (Lillludited)

(Uo• uJil•d) (Uniudirtd) (t\udltod) Rrfi1r 't'ntr- 8

~328 08 Ill CJ4J ~3 &<1.1)4) 0<1 ·~.'13() ss 76,11818

IUb 74 llZ 13 5J9 54 15 1 19 811..12

U,SH.8l 19,2G~88 GS,492.113 56,681.1}4 76.9.19~~0

S,l 6SJO 4,1&2.59 13,31') 20 12.~<ll 11 HI Ol

l$2 10 ll115 JJ9 J8 lSA bO 55111

·I 057 08 4.~b~.RI 14,-S:t.l S7 1317208 116:20 il

IQO '11 J8.S6 1106 7~ 4HS 3~ II

92892 SJO 13 1,81~ j O 1,461 •12 ~.006 6 1

M86 8S 5,2?, 52 16.528 46 14 8'84 66 20.5SH8

17.185.12 14,670.76 50,2\9,6~ .0,1)5.41 311,141.30

'11'1 70 ~,5'lS 12 ts~nOQ 13,566 6! l8.'i'l8.20

t.llO ~8

S,3l970 4 sos I ~ 1•1.586 51 13.56662 18.iQ8 !0

(IUOol (4393) '" 98) UO-! OJ ) (143 OZ)

S,JlQ.6q ""~~ 1 . 1 9 1-ln~J-l,SJ ll,J G1.6l 18,655.18

076 "t> I Jg755 Jl11 84 J.SS-1 so 6 JOCIOJ

Jl JS [1<12•!1 (-43 Q) o:Q (IHll

1,007.6 1 1,~18.31 J,3l8M ~,$ll.l,78 6,293.90

~,3 1 3.03 3,132.88 ll.lOS.88 s,sn.SJ ll.J61.l8

11 711 8·:1 bl82 em s 1 JlJ3 IO 'lo

(1 7 ll7) 11>782 C) (b 140 I I 891~

( 1~4.Al) 170.6-l (172.95) 183.-U 130.18

~.118.11 3,31!3.52 l i ,O.H.93 9,06 1.17 12.51\0.56

4..:~n" J,)lOJb II 183 21 8~6b 18 :~o.; TQ

14 'lR 12 52 22 ot l I 65 )4040

(1<14 SS) toO 55 ( 17~ 6") ·~3 00 l"ft I~

(0 ~J) 'C<l lOB) 044 I~~

~ O.l .17 3~80QJ II 01 b5 8 '1~'11 8 1:!.1~' <)J

- 75 11 bl ::.:: l8 l'1 co 1-1'7 113

lllll' H I.OIJ1 )7 I,Pfl• •7 I 00l.S7 • ti!1S7

.; t,')')(,Cll

8 S7 ,, .. 6 ~-' ·o 1'8 24Ll0

1.:0:!

Metropolis H ealthcare Limited Regi~t11rod Oflk<u l50 0. Udy<lg ~-an. Hind Cycl~ H•rg, Wofll, Mumbal - 400 OJ CIN: U7J I OOMH2000PLC 191799. Tel: +91 ·21· 3399 3939 I 6650 SSSS.

Email: support@mecropolislndl~ com I Wab•ite: www met.ropoli~indi.t..eorn

Central Ll\boratory: ~ch Flonr. Commcrci~l Suildln&· l A, Kohlnoor Mall, Vldyavlhar (yV). Mumbal - 400 070.

\>letropollli Hc•llhcMrt Lumu,d

\ OlF: 1 Thc>e financ1:tl resuhs h,\Ve been pn:pan.:d in accnrdun.-:c with the n:cog:nltlun und m~asurcmcut pnnc.1ples ol lndmn Accnunung Standnrds ("lnd

AS'') prcsc.rfhed under ec.unn 133 of the Companies AcL10 13 read w11h the relevant rule~ 1ssucd thereunder and the otho:r :u:cuunung pnnc1ple.~ gcn~mlly Rct~ptcd 1n lndta

The abov~ unaudrtcd re>ults were rev:ewe.d by the Aud1t Cnmmtttec at their mc.:t111g held On 6 February 2020 and the~aftc:r approved by the Board of Directors at their mec:ring J)eld on() r'cbruruy 2020 The stntutOt)' nud1tors have expressed an unmodified review opm1on

3 Metropolis Ht:althcarc Lnmtcd (the 'Company' or the ' Parem'). and Its subsid:anes (referred to collecuvcly as the 'Group') ond tiS JOint venture arc pnmarily invl)lvcd 111 providtng pathology and rela1cd h<1illthq~re services .

rhc Grl)up hi\S adopted lnd AS lib. effecuve annual reporttng period beginning 01 Apnl 2019 ond applied the sLBndard to itS lenses. retrospcetivcl>, wtUt Ute liumularive etTect of initial! applying the Stfmd!trd. recognised on the dnte of tnllial applicatJon (OJ Apnl 2019) Accordingly thE' Group h=~S not rcstntcd comparnt.ive informauon. mstcad the cumulattve effect of mltlally applymg this ~tondard has betn recogn:sed as an adjustment to the openmg balarlcc of retamed eanungs as on 01 April 2019 The Group ha.~ udoptcd lud AS 116 using the cumuluuvc eflect method for trunsHiontng

s EJic;eptlonalttCm.~ 111 the cons(lltdatcd financial results for the nme !llOnths ended 31 December 20 I 9 l nclud~s: -

a) provisi(ln for 1mpu1rmcnt oflnve~tment 111 secunues of lnfrasttucturc Leasing & Financial Services (IL&FS) aggregating to Rs 316.48 Lukh~ and. b) provision for Rs350.00 l.ltkhs on account of cenain old unrcconcllcd balances

6 Disclosure of segment wise information ts not npphcable. as patholog) ~~rYlccs ts the Group's only business segment

7 The Company completed an ln111al Public Offer through !ll1 offer (or sale: by the sellln~ shureholdcrs of IJ6,85.095 equity shares of Rs.2 each at pncc of Rs 880 The equ11y shares of the Company got li~tc:d on Ute DSE l.lmtted and Nauonal Stock Exchl\llge of India Limited on 15 April 2019 E'<penses rei:Ucd to the offer are b.:mg arc being borne: by sclli.ng shareholders.

8 Th~ C'on.olidat<!d finnnctal results for ihc quarter ended 31 December 2018 and nmc month~ ended 31 De(;(:mbc:r 2018 were not sub;ected to limited review b)' the Statutory audHors and are as prepared by the Parents' :mmagc:mcnt

Q The Company has through 1ts wholly owned ~ubsidttll) "De.o.m \lletropoli, Health crvice;. Pnvate Ltmited'' hi\S acquired 4 (four) Labnratoncs frnm· (1) Doctor's Cltntcal Laboratory (partnership finn) . (ii) lyer PnthoiOg} Lnhomtol) (golc propnctary). (ul) ~agar Puthulogy LaboratOry (sole propnctary) and (1v) Yn..h Chn1cal Labordtory (sole proprietnry). lor providing diagnostic nnd pathological tcsting serv1ccs in Surill Gu.tamt as on 30 September 2019 for purchase cun~ldc:rpuon ofRs. 1,800 lokhs pa)nble m 3 trnnclles stflltlng from 30 September 2019

to The Cnmpany is in process of acqumng 51 % snarcho1diug ol Shraddhn Dingnosllc Centre! (I) Pnvate L:m:tcd tor provtdtng diagnostic and patholog:caltestiny services in Ahmedabad, Gu,Jarat as approved m Board M~ellng held on I Sth January 2020 to strengthen the presence of the Company In the stato of GuJurnt r.or purchase consideration of Rs 936.30 l nkh~ The same is exp~I\Jd to be closed within three months from the date of npprovnl or the Board

'1 Tite Board ofDtrcctors of the Company have approved the interim d:v:dcnd ofRs. 8 per equity shnn: (Face value orRs 2 each) nt the mccung held on Ob Febru!U') 2020

t2 "rhc Company and its Indian subsJd:ury companies have elected to ~xc:rc1se the opuon permitted tmder sectlon 11 SBAA of the lncome-ta.\ Act, 1961 as introduced by the: ra.l(ation Laws (Amendment) OrtliJIWIC;!. 2019 ,\~wrdmgly the Company and Ci:rlllin subsidillr) cnmpani.:s have recognised Provisio11 of Income Tax for the nine months end.:d 31 December 2019 and re-rueoc.ured tts Deferred Ta;'i basts the rnte prescribed 111 the snii.l secnon The lulltmpacr of th:s change ha~ been recognls~d in the Statement of Profit & Loss for the quurter ended 30 ~eptcmbcr 201 9lJnd n:ne m1mths penod ended 31 Decem her 20 l9

IJ

\m~era Shah 1\'hnngl n~ Director

J>J:X:0020809S

Place \1untbni Date !)(t Fchrllllr)' 20:;!0

METROP&;)LIS The Pathology Specialist

INNER HEALTH .REVEALED Metropolis Healthcare Limited Reghternd O ffi,e: 250 D, Udyog Bhav•n. Hind Cycle Marg, W orli, Mumbal - 100 030.

CIN: U73100MH2000PLCI92798. Tel: +91·22-3399 3939 / 6650 SS5S.

Em•il: $1!pport@metropoli~lndla.corn I Wcb5it~ www mettopolisindla com C entral L.aboratory: 4th Flonr, Commc"i~ l Building-lA. Ko~lnoor Mall, Vidya•lhar (W). Mumbal - 100 070.